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Lipopolysaccharide pretreatment attenuates myocardial
infarct size: A possible mechanism involving heat shock
protein 70 –inhibitory B complex and attenuation of
nuclear factor B
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Noriyuki Tabuchi, MD
Hiroyuki Tanaka, MD
Makoto Sunamori, MD Objective: Lipopolysaccharide pretreatment is known to reduce myocardial infarct
size, but the mechanism has not been elucidated. We hypothesized that heat shock
protein 70, induced by lipopolysaccharide pretreatment, formed complexes with
inhibitory B, thereby inhibiting degradation and attenuating activation of nuclear
factor B and cellular injury in rat myocardium.
Methods: Fifteen Sprague-Dawley rats were given saline solution (control group) or
lipopolysaccharide. After 48 hours, 5 hearts in each group were excised without
ischemia for examination of heat shock protein 70 and inhibitory B levels and
detection of heat shock protein 70-inhibitory B complexes. Myocardium from the
remaining 10 rats in each group was exposed to 30 minutes of ischemia and 30
minutes of reperfusion (n  5) to evaluate nuclear factor B activity or to 24 hours
of reperfusion (n  5) to evaluate infarct size.
Results: Infarct size was reduced in the lipopolysaccharide group (P .05). Nuclear
factor B was activated in the control ischemia group and attenuated in the
lipopolysaccharide group (P  .05). Heat shock protein 70 levels were increased in
the lipopolysaccharide group (P  .05), but inhibitory B levels were similar in
both groups. Heat shock protein 70–inhibitory B complexes were detected only
in the lipopolysaccharide group. Colocalization of the 2 proteins was observed in the
lipopolysaccharide group.
Conclusions: Heat shock protein 70, induced by lipopolysaccharide pretreatment,
forms complexes with inhibitory B and attenuates activation of nuclear factor B
and myocardial infarct size. Our results suggest that attenuation of nuclear factor B
through a mechanism forming heat shock protein 70–inhibitory B complexes
might protect the myocardium from ischemia-reperfusion injury.
Myocardial reperfusion injury occurs to various degrees duringcardiac operations.1 Many methods to prevent myocardialinjury caused by ischemia and reperfusion have been exam-ined. Early (immediate) or delayed (24-72 hours later) pre-conditioning of the heart is a promising procedure, resultingin cardiac protection by means of different phenomena and
mechanisms.2,3 It is reported that ischemic preconditioning2 and pharmacologic
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pretreatment4 showed protection in the early phase, whereas
ischemic preconditioning,3 heat stimuli,5 monophosphoryl
lipid A,6 and interleukin 1 pretreatment7 have been reported
to reduce ischemia-reperfusion injury and to prevent hemo-
dynamic depression after ischemia in the delayed phase.
Lipopolysaccharide (LPS) pretreatment is also known as
delayed preconditioning and is used to enhance cellular
tolerance to ischemia in various organs, including the liver,8
kidney,9 brain,10 and heart.11,12 In LPS-treated hearts it was
shown that LPS increased levels of heat shock protein 70
(HSP70),11 and investigators have shown that myocardial
protection reduces infarct size11 and maintains cardiac func-
tion,12 which is associated with the HSP70. HSP70 func-
tions as a chaperone, folding and transporting newly syn-
thesized proteins and degrading damaged proteins.13 When
expression of HSP70 is induced in cells exposed to stress,
HSP70 often rescues cells from death through its chaperone
function. In the myocardium HSP70 is induced 24 to 72
hours after LPS pretreatment11 and ischemic precondition-
ing.14 However, there is no evidence that HSP70 directly
attenuates ischemia-reperfusion injury in the myocardium.
In the process of myocardial infarction, the transcription
factor nuclear factor B (NF-B) plays a role in the regu-
lation of cellular function.15,16 NF-B is involved in inflam-
matory processes and promotes transcriptions of multiple
depressive cytokines. NF-B is a ubiquitous, inducible tran-
scription factor that exists as a latent cytoplasmic form
complexed primarily with p50 and p65 bound to inhibitory
B (IB) proteins.15,16 IB proteins consist of several sub-
types, but IB is thought to play an essential role.15,16
Once IB is phosphorylated16 by any stimuli, it is disassoci-
ated from the most common form of the NF-B, and IB
permits translocation into the cardiomyocyte nucleus with
transcriptional regulation of multiple depressive cytokines,
such as tumor necrosis factor. NF-B translocates from the
cytosol to the nucleus in a process called NF-B activation.
We hypothesized that increased levels of HSP70, which
forms complexes with IB and inhibits its degradation,
lead to attenuation of NF-B activation and reduction in
myocardial infarct size. We tested our hypothesis in hearts
of LPS-treated rats.
Materials and Methods
This investigation was performed in accordance with the “Guide
for the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press, revised
1996. Our protocol was also approved by the Committee of Ani-
mal Experiments at Tokyo Medical and Dental University (Prin-
cipal Guideline for the Use of Laboratory Animals in Tokyo
Medical and Dental University, published 1988).
Experimental Procedure
Male Sprague-Dawley rats (body weight, 250-300 g) were accli-
mated in a quarantine room and maintained on a standard pellet
diet for 10 days without any stresses. LPS (Escherichia coli,
O-127) was purchased from Sigma Chemical Company (St Louis,
Mo). The experimental procedure is shown in Figure 1. We estab-
lished 3 experimental groups: the sham operation group (intraperi-
Figure 1. Experimental procedure. There are 3 groups: sham operation, control, and LPS groups. HSP, IB, complex
indicates preparation of samples for measurement of protein levels, detection of HSP70y-IB complexes, and
immunostaining (n  5 in each group). NF-B indicates preparation of samples for evaluation of NF-B activities
(n  5 in each group). Infarct size indicates preparation of samples for measurement of infarct size (n  5 in each
group).
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toneal saline solution, 2 mL; n  5); the control group (intraperi-
toneal saline solution, 2 mL; n  15); and the LPS group
(intraperitoneal LPS, 3 mg/kg; n  15). At 48 hours after LPS
administration, 5 rats each in the control and LPS groups were
anesthetized with ketamine (40 mg/kg administered intraperitone-
ally), and hearts were rapidly excised without ischemia and ar-
rested in cold phosphate-buffered saline solution (PBS). The apex
of the left ventricle was cut and prepared in OCT compound
(Tissue-Tek; Sakura, Tokyo, Japan) for immunohistochemistry.
The remaining left ventricle was frozen in liquid nitrogen for
evaluation of the HSP70 and IB protein levels and for detection
of HSP70-IB complexes. The remaining 10 rats in the control
and LPS groups and 5 rats in the sham group were used in
ischemia-reperfusion experiments. Each of the rats was anesthe-
tized with ketamine, intubated, and ventilated. After left thoracot-
omy, the left anterior descending coronary artery was occluded for
30 minutes and reperfused either for 30 minutes for evaluation of
NF-B activation (all groups, n  5 in each) or for 24 hours for
assessment of infarct size (control and LPS groups, n 5 in each).
To confirm whether HSP70-IB complexes are present in
myocytes, we used neonatal rat cardiomyocytes. The cardiomyo-
cytes were cultured and stimulated with LPS for 48 hours to detect
HSP70-IB complexes.
Evaluation of Infarct Size
Infarct size was evaluated as described previously.17 After 24
hours of reperfusion and after the 30-minute period of ischemia,
hearts were excised and arrested in ice-cold PBS. The left anterior
descending coronary artery was ligated, and 1% Evans blue dye
solution was injected through the ascending aorta to determine the
risk and nonrisk areas. The heart was cut into 2-mm-thick slices,
and the second slice from the ligation was stained by means of
incubation at 37°C for 20 minutes in 1% triphenyl-tetrazolium-
chloride in PBS (pH 7.4). Slices were then scanned with a com-
puterized scanner, and total area, nonrisk area, and infarct area
were measured with Scion Image software (Microsoft Corporation,
Redmond, Wash).
Preparation of Nuclear Extracts and Electrophoretic
Mobility Shift Assays
After 30 minutes of reperfusion and 30 minutes of ischemia, hearts
were excised. Nuclear proteins were prepared with a modification
of the method described by Dignam and colleagues18 and Manning
and coworkers.19 In brief, the left ventricle of the risk area was
homogenized in 5 mL of buffer A (N-2-hydroxyethylpiperazine-
N-2-ethanesulfonic acid, 10 mmol/L; MgCl2, 1.5 mmol/L; KCl, 10
mmol/L; dithiothreitol, 1 mmol/L; and phenylmethylsulfonyl flu-
oride, 1 mmol/L) with a Dounce homogenizer (Bellco Glass, Inc,
Vineland, NJ). The samples were centrifuged at 900g for 10
minutes. The pellets were dissolved in 5 mL of buffer A and 0.1%
Nonidet P-40 and recentrifuged at 200g for 10 minutes to eliminate
unbroken cells. The supernatant was collected and recentrifuged at
900g for 10 minutes. The pellets were washed once with buffer A
and purified by using the modified sucrose-gradient method.20 The
pellets were dissolved in 50 L of buffer B (N-2-hydroxyethyl-
piperazine-N-2-ethanesulfonic acid, 20 mmol/L; glycerol, 25%
vol/vol; NaCl2, 420 mmol/L; MgCl2, 1.5 mmol/L; ethylenedia-
mine tetra-acetic acid, 0.2 mmol/L; dithiothreitol, 1 mmol/L; and
phenylmethylsulfonyl fluoride, 1 mmol/L), incubated for 45 min-
utes on ice, and centrifuged at 20,000g for 20 minutes. The
supernatant was collected, and the protein concentrations were
measured with the bicinchoninic acid method (Amersham Corp,
Arlington Heights, Ill).
An electrophoretic mobility shift assay was performed to eval-
uate NF-B activity, as described previously.19 Twenty micro-
grams of each nuclear protein sample was incubated with an
end-labeled double-stranded oligonucleotide probe, which had the
NF-B consensus sequence 5-AGT TGA GGG GAG TTT CCC
AGG C-3 (Promega Corp, Madison, Wis); [-32P] adenosine
triphosphatase (3000 Ci/mmol, Amersham); and T4 polynucle-
otide kinase (Amersham) according to the manufacturers’ proto-
cols. The DNA protein complexes were separated on 4% nonde-
naturing polyacrylamide gels, and the gels were vacuum dried and
exposed to Image-Plate (Fuji Film, Tokyo, Japan) overnight at
room temperature. Specific band intensities were quantified with
the FLA 3000 fluoroimage analyzer (Fuji Film) and analyzed with
the ImageGauge analyzing system (Version 3.12, Fuji Film).
Western Blotting and Immunoprecipitation
HSP70 and IB protein levels were examined by means of
Western blotting. In brief, a small part of the excised frozen left
ventricle was thawed and homogenized in 1.5 mL of buffer A with
a Dounce homogenizer. After centrifugation (10,000g for 30 min-
utes), the supernatants were collected, and the protein concentra-
tions were measured by using the bicinchoninic acid method. Forty
micrograms of each sample was separated by means of electro-
phoresis on a 10% denaturing sodium dodecyl sulfate gel. After
electrophoresis, the proteins were transferred electrophoretically to
polyvinilidene difluoride membrane (Bio-Rad Laboratories Inc,
Hercules, Calif) overnight at 4°C. The membrane was incubated in
2% nonfat dry milk and 0.2% Tween-20 in PBS followed by
incubation with specific anti-IB antibody (anti-rabbit poly-
clonal, C21, Santa Cruz, Calif) or anti-HSP70 antibody (anti-
mouse monoclonal, W27; Santa Cruz). After extensive rinsing
with Tween-PBS, blots were incubated with horseradish peroxi-
dase–conjugated anti-rabbit and anti-mouse secondary antibody
and developed with the enhanced chemiluminescence system
(ECL kit, Amersham). The developed films were scanned with a
computer scanner, and the intensities of the bands were measured
with Scion Image software (Microsoft).
HSP70-IB complexes were detected by means of immuno-
precipitation and Western blotting. In brief, 200 g of cytosolic
extracts was incubated with 20 L of Protein G-Sepharose (Amer-
sham). After centrifugation (10,000g for 5 seconds), 5 g of
anti-HSP70 antibody was added to the total supernatants. After a
1-hour incubation at 4°C, 20 L of Protein G-Sepharose was
added to each sample. After centrifugation (2000g for 5 minutes),
the pellets were collected and washed 5 times with Buffer A. The
precipitates were examined by means of Western blotting with
anti-IB antibodies. The blots were developed with the ECL
system (Amersham).
Immunohistochemistry
Immunofluorescent staining of IB with rhodamine-conjugated
anti-rabbit IgG antibody (23828, Polysciences, Inc, Warrington,
Pa) was performed as described previously.21 After staining,
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immunofluorescent staining of HSP70 with FITC-conjugated anti-
mouse IgG antibody (23799, Polysciences) was performed. Immu-
nofluorescent images were obtained with a ZEISS LSM510 laser-
scanning confocal microscope (Carl Zeiss Corp, Stuttgart,
Germany).
Statistical Analysis
Results are expressed as means  SEM. Data were analyzed by
means of analysis of variance. If the analysis of variance showed
an overall difference, post hoc comparisons were performed with
the Bonferroni-Dunn test for paired or unpaired data, as appropri-
ate.
Results
Reduction of Infarct Size
Representative slices of left ventricle from control and LPS
rats at 24 hours of reperfusion and 30 minutes of ischemia
are shown in Figure 2. The infarct area was reduced in the
LPS group, and the results of these measurements are shown
in Figure 3. The risk/total area ratio was similar in both
groups (53.51  2.90 for the control group and 54.26 
2.98 for the LPS group), but the infarct/at-risk area ratio was
significantly less in the LSP group (31.30  2.01) than in
the control group (57.05  0.85, P  .0001).
Change of NF-B Activation
The results of using electrophoretic mobility shift assays to
evaluate NF-B activation after 30 minutes of reperfusion
are shown in Figure 4. NF-B bands in the control group
were significantly more intense than those in the sham-
operated group (2.35  0.17 for the control group and
1.00  0.10 for the sham-operated group, P  .0001).
NF-B bands in the LPS group were significantly less
intense than those in the control group (1.86  0.21 for the
LPS group, P  .0039).
Changes of HSP70 and IB Protein Levels
At 48 hours after LPS administration and before ischemia,
HSP70 and IB protein levels in the cytosol were exam-
ined by means of Western blotting (Figure 5). HSP70 levels
in the LPS group were higher than those in the control group
(1.00  0.07 for the control group and 1.25  0.08 for the
LPS group, P  .0469). However, IB levels were similar
in both groups (1.00  0.10 for the control group and
0.98  0.17 for the LPS group).
Detection of HSP70-IB Immunocomplexes
At 48 hours after LPS administration (before ischemia),
immunoprecipitation and Western blotting were performed.
The results are shown in Figure 6. HSP70-IB complexes
are visible as IB bands. HSP70-IB complexes were
present at detectable levels only in the LPS group (Figure 6,
bottom).
Immunohistochemistry analysis showed that IB den-
sities were similar in both the control and LPS groups
(Figure 7, A and C), but HSP70 was stained more strongly
in samples from the LPS group than in samples from the
control group (Figure 7, B and D). A confocal image of a
sample from the LPS group is shown (Figure 7, E). Local-
ization of IB (red; Figure 7, C) and HSP70 (green; Figure
7, D) was identical, suggesting the presence of complexes,
Figure 2. Representative slice of left ventricle from rats of the control and LPS groups after 30 minutes of ischemia
and 24 hours of reperfusion. Slices were stained with triphenyl-tetrazolium-chloride. The violet region corresponds
to the nonrisk area. The red region is the risk area, and the white portion is the infarct area.
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as shown in yellow in the merged image (Figure 7, E,
arrows).
Discussion
In the present study we investigated the role of HSP70 in
attenuation of NF-B activation in rat hearts and cultured
myocytes. HSP70 expression was induced by means of LPS
pretreatment, and HSP70-IB complexes were formed.
These complexes subsequently attenuated NF-B activa-
tion. These changes appeared to be associated with a reduc-
tion of infarct size in rat hearts after ischemia and reperfu-
sion.
Regarding the method of measuring the risk area of the
heart, we used Evans blue dye (molecular weight 960.8 d),
according to the method of Yamashita and colleagues.17 It is
criticized that dyes with a small molecule, like Evans blue,
used for measuring the risk area might perfuse into the
nonperfused area. However, zinc cadmium sulfide micro-
spheres (1- to 10-m diameter) used for this purpose re-
sulted in a similar risk area to ours.22
Resistance of cells to various forms of injury is induced
by LPS, and this resistance has been studied in the liver,8
kidney,9 brain,10 and myocardium.11,12 In myocardium LPS
pretreatment was reported to reduce infarct size in relation
to HSP70 levels9 and to improve cardiac function after
ischemia and reperfusion.12 Various mechanisms for the
Figure 3. Measurement of infarct area ratios (n  5 in each group): A, average ratio of risk/total area; B, average
ratio of infarct/risk area. Results are expressed as the mean  SEM. *P < .0001 compared with control.
Figure 4. NF-B binding activities of nuclear proteins in each group after 30 minutes of ischemia and 30 minutes
of reperfusion: A, representative NF-B band in each group; B, ratio of average intensities of all NF-B bands in
each group. The average of the sham group was considered to be 1.00. NC, Negative control (protein absent); Sham,
sham operation group (no ischemia). Results are expressed as the mean  SEM (n  5 each group). *P  .0001
compared with sham operation group, and #P  .0039 compared with control group.
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protective effects of LPS pretreatment have been proposed:
(1) alteration of inflammatory mediators from monocytes
and macrophages23; (2) downregulation of the expression of
endothelial cell adhesion receptors, which could account for
decreased tissue sequestration of neutrophils24; (3) effects
of the NO system25; and (4) increased myocardial capillary
density.26 However, the precise mechanism underlying
HSP70-associated reductions in infarct size or improvement
of cardiac function is not yet well understood.
It is generally agreed that expression of HSP70 increases
24 to 72 hours after cells are exposed to various stimuli,
including LPS,10 heat shock,5 and ischemic precondition-
ing.14 Our previous data showed HSP70 was detected most
strongly at 48 hours compared with at 24 or 72 hours by
LPS administration (data were not shown). We decided to
use the condition of 48 hours. LPS was administrated in-
traperitoneally at 3 mg/kg, which is among the amounts
used by other investigators.12,27 The levels of HSP70 after
Figure 5. Levels of HSP70 and IB proteins in control and LPS group samples at 48 hours after LPS administration:
A, representative bands and statistical analysis of HSP70; B, representative bands and statistical analysis of IB.
Open arrowheads indicate HSP70 and IB bands, and filled arrowheads indicate nonspecific bands. M, The 65-kd
and 45-kd markers.*P  .0469 compared with the control group.
Figure 6. Immunoprecipitation followed by Western blotting 48 hours after administration of LPS. The 10 different
lanes correspond to each sample from 5 rats of the control group and 5 rats of the LPS group. M, The 65-kd marker.
Samples were immunoprecipitated with anti-HSP70 and then examined with anti-HSP70 (A, top panel) and
anti-IB (B, bottom panel) by means of Western blotting. In B the immunocomplex was visualized as IB bands
only in the LPS group.
Cardiopulmonary Support and Physiology Shimizu et al
938 The Journal of Thoracic and Cardiovascular Surgery ● November 2002
CSP
LPS pretreatment in our study were consistent with those of
other studies.
HSP70 has a chaperone function, folding newly synthe-
sized proteins, transporting them, and degrading damaged
proteins.13 Of these functions, degradation of damaged pro-
teins is particularly important. HSP70 is known to affect the
ubiquitin-dependent proteolysis system.28 Most proteins in
the cytosol exist in a soluble form, with hydrophilic amino
Figure 7. Colocalization of IB and HSP70 in the myocardium: A, myocardium from the control group sample
stained with anti-IB antibody, followed by rhodamine-conjugated second antibody (red); B, the same myocar-
dium stained with anti-HSP70 antibody, followed by FITC-conjugated second antibody (green); C, myocardium from
LPS group rats as in A; D, LPS group myocardium stained as in B; E, merged image of IB (C) and HSP70 (D)
staining in the LPS group; and F, low magnification of C, D, and E. Colocalization of IB and HSP70 is shown as
yellow speckles (arrows).
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acids on the outside and hydrophobic amino acids in the
core. When these proteins are damaged by various stresses,
the molecular structure is changed to expose the hydropho-
bic residues to the exterior of the protein. The damaged
proteins begin to aggregate to form insoluble pellets, and the
proteins are subsequently degraded by proteolysis.28 During
this process, HSP70 binds to the hydrophobic surface of the
damaged proteins to prevent aggregation. In the reperfused
ischemic myocardium, many damaged proteins might be
affected by the chaperoning function.
The NF-B activation consists of 2 processes, transloca-
tion to the nucleus and binding to DNA, and both of the 2
activation processes are controlled by redox regulation.15,16
Dissociated IB is polyubiquitinated by ubiquitin ligase
and degraded through 26S proteosome proteolysis.16 Thus,
NF-B activation can be inhibited through 2 possible path-
ways: the reduction of various reactive oxygen species and
the prevention of the IB degradation process. Theoreti-
cally, HSP70 might affect both pathways; however, to our
knowledge, there have been no reports of attenuation of
NF-B activation by HSP70. Therefore, we focused our
analysis on the pathway in which HSP70 directly affects
IB.
In the present study IB protein levels were not signif-
icantly different in hearts from control and LPS group
animals at 48 hours after administration of LPS. Whether
IB levels are increased at 48 hours after LPS adminis-
tration remains controversial,29 but our results indicate that
the myocardium had attenuated NF-B activation and in-
creased tolerance to ischemia without increased IB lev-
els. These results suggest that mechanisms other than an
increase in IB expression might exist. Thus, we hypoth-
esized that HSP70 forms a complex with IB, attenuating
NF-B activity, and our experiment revealed formation of
HSP70-IB complexes.
How the HSP70-IB complex acts during the process
of NF-B activation is still unclear. HSP70 might bind
IB to prevent its phosphorylation by IB kinase, or
HSP70 might inhibit IB kinase directly. It is also possible
that the HSP70-IB complex inhibits the IB kinase in-
directly. Although we observed formation of complexes
between IB and HSP70, it is still unclear whether HSP70
forms a complex with IB/NF-B dimers or with IB
protein during degradation. It is also unclear whether
HSP70 affects IB through unknown proteins derived
from pathways triggered by extracellular stimuli. Immuno-
precipitation with anti-HSP70 antibody and anti–NF-B
antibody, Western blotting with anti-phosphorylated IB
antibody, and Western blotting with anti-ubiquitin antibody
should be investigated to confirm that in vivo inhibition of
NF-B translocation during myocardial ischemia-reperfu-
sion injury is secondary to HSP70 interference with IB.
This is the first report of IB stabilization because
formation of complexes with HSP70 attenuates NF-B ac-
tivation. We proposed that there is cytoprotective effect of
LPS by delayed preconditioning and a certain mechanism of
the protection. As for LPS cytotoxity, the signaling of LPS
into the cardiomyocyte and into the myocardial resident
macrophage has been well worked out. LPS is typically
bound by a circulating LPS binding protein, which typically
docks on toll-like receptor 4. The intracellular extension of
toll-like receptor 4 binds to an adaptor protein (MYD88),
which then links to interleukin 1 receptor–associated kinase,
which can activate tumor necrosis factor receptor associated
factor. Through a subsequent series of kinase activations,
IB is phosphorylated, and NF-B is activated.30 Compared
with studies of LPS cytotoxity, the mechanism of LPS
cytoprotection is not elucidated enough. Direct administra-
tion of LPS is not allowed clinically, but pharmacologic
preconditioning, such as that with monophosphoryl lipid A,
is known to induce delayed preconditioning effects, such as
LPS.6 Our results suggest that attenuation of NF-B by the
mechanism of HSP70-IB complexes plays a clinically
relevant role in the reduction of infarct size.
In conclusion, we show that HSP70 induced by LPS
pretreatment forms complexes with IB and inhibits IB
degradation and NF-B translocation into the nucleus, re-
sulting in a reduction in myocardial infarct size.
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